Research summary ·
ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms: a systematic review.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review looked at ATM gene changes in myeloid cancers. They included MDS, AML and MPN. ATM is a kinase in the DNA damage response. The team asked what ATM changes mean for outcome and biology. The review was registered with PROSPERO.
What they found
In MDS, ATM showed lower activity, extra methylation and many harmful mutations. Methylation was more common in cases that went on to AML. In AML, lower ATM activity went with faster blast growth. The variant rs3092856 went with drug resistance and worse survival. Evidence in MPN and CML was limited. It suggests some ATM variants add to disease risk and poorer outcome.
What it means for patients
The authors say ATM changes look like clinically relevant markers in myeloid cancers. They say its role in how disease starts is not fully clear. They say future work should look at ATM-linked treatment weak points.
Why it is not certain yet
Evidence in MPN and CML was limited. The role of ATM in disease origin is not fully understood. The review does not show that ATM changes cause poor outcomes. A review can only be as good as the studies in it.
Source
ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms: a systematic review.
PubMed · PMID 42789026We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Myelodysplastic syndromes publications